Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart
failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin …

Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an
underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils …

The systemic amyloidoses are a broad spectrum of diseases that result from misfolding of
proteins that aggregate into b-sheet amyloid fibrils. Over 35 amyloidogenic precursor …

Background: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly
recognized cause of heart failure in older individuals. We sought to characterize the natural …

Although care of patients with heart failure (HF) has improved in the past decade, important
disparities in HF outcomes persist based on race/ethnicity. Age-adjusted HF-related …

Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly diagnosed owing to the
emergence of noninvasive imaging and improved awareness. Clinical penetrance of …

Background: Tafamidis is approved in many countries for the treatment of transthyretin
amyloid cardiomyopathy. This study reports data on the long-term efficacy of tafamidis from …

Advances in cardiac imaging have resulted in greater recognition of cardiac amyloidosis in
everyday clinical practice, but the diagnosis continues to be made in patients with late-stage …

Background: Patients with cardiac amyloidosis often have carpal tunnel syndrome that
precedes cardiac manifestations by several years. However, the prevalence of cardiac …

Background: Transthyretin amyloidosis (ATTR) is a heterogeneous disorder with multiorgan
involvement and a genetic or nongenetic basis. Objectives: The goal of this study was to …